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Abstract Parvovirus B19 (PB19) is a common, widespread,
small, single-stranded DNA virus which has been linked with
a broad spectrum of clinical illnesses, including a variety of
neurological complications such as encephalitis, meningitis, my-
elitis, stroke, cerebellar ataxia, and neuropathy. The authors de-
scribe a case of PB19 infection associated with hemolytic ane-
mia and cranial polyneuropathy involving the second and third
cranial nerves in a 23-year-old immunocompetent woman. The
diagnosis of acute PB19 infectionwas establishedwith detection
of positive DNA and anti-PB19 IgM antibodies in blood sam-
ples. Antiganglioside antibody studies were performed and se-
rum anti-GD1b IgG was strongly positive. Further investigation
was normal or negative, excluding other infectious or autoim-
mune disorders. The patient was initially treated with a 5-day
course of intravenous immunoglobulin (IGIV). Because of in-
complete neurological recovery, methylprednisolone was also
administered 7 days after IGIV therapy initiation. Complete res-
olution of clinical symptoms was observed 3 months after dis-
ease onset at follow-up visit, despite the persistence of PB19
DNA and anti-PB19 IgM antibodies in serum 5 months after
the initial presentation. Our report provides evidence that PB19
could affect both the central and peripheral nervous system,
possibly by triggering an autoimmune mechanism that leads to
autoantibody production.
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Introduction
Parvovirus B19 (PB19) is a common, widespread, small,
single-stranded DNA virus which has been linked with a
broad spectrum of clinical illnesses, ranging from self-
limiting erythema infectiosum in the healthy host to life-
threatening complications in immunocompromised patients
(Qiu et al. 2017; Broliden et al. 2006). In rare cases, PB19
infection could be related with less commonly recognized and
infrequently reported neurological manifestations. We de-
scribe a case of PB19 infection associated with cranial
polyneuropathy and hemolytic anemia in a 23-year-old immu-
nocompetent woman.
Case report
Apreviously healthy 23-year-old woman presented to our emer-
gency department with a 2-day history of acute right eye pain
during eye movement followed by ipsilateral blurring vision,
pupillary asymmetry, and double vision 2 weeks after a sponta-
neously resolved diarrheal episode. Neurological examination
showed an uncorrected visual acuity of 7/10 in her right eye
and a relative afferent pupillary defect, anisocoria with an ipsi-
lateral dilated pupil, paresis of right eye adduction, and vertical
diplopia in all directions of gaze. The remaining clinical exam-
ination was otherwise normal. Cerebral computed tomography,
brain magnetic resonance imaging (Fig. 1), and magnetic reso-
nance angiography were normal. Initial laboratory testing re-
vealed a mild increase of total bilirubin (1.85 mg/dL; normal
range < 1.20 mg/dL) and direct bilirubin (0.52 mg/dL; normal
range < 0.50 mg/dL) levels, whereas other liver and renal func-
tion tests, hemoglobin, white blood cell count, erythrocyte sed-
imentation rate, and C-reactive protein were normal.
Autoimmune screening was negative for antinuclear antibodies,
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antineutrophil cytoplasmic antibodies, antithyroid antibodies,
and serum angiotensin converting enzyme. Antiganglioside an-
tibody studies were performed and serum anti-GD1b IgG was
strongly positive. Cerebrospinal fluid (CSF) exhibited normal
cell count and protein level, absence of IgG bands or intrathecal
IgG synthesis, and the presence of a damaged blood-brain bar-
rier. Serological tests in serum and CSF excluded active infec-
tion due to enterovirus, herpes simplex virus 1 and 2, varicella
zoster virus, cytomegalovirus, Epstein-Barr virus, hepatitis B
virus, hepatitis C virus, human immunodeficiency virus 1 and
2, Treponema pallidum, and Borrelia burgdorferi. Additional
blood investigations displayed positive anti-PB19 IgM (3.20;
positive ≥ 1.0) and IgG (40.90; positive ≥ 1.0) antibodies, and
PB19 DNA was detected using polymerase chain reaction
(PCR). Search for PB19 DNA in CSF with PCR was
negative. A diagnosis of PB19-associated cranial
polyneuropathy involving the second and third cranial
nerves was made and the patient was initially treated with
a 5-day course of intravenous immunoglobulin (IVIG)
30 g/day. Because of incomplete neurological recovery,
methylprednisolone 1 g daily for 5 days was also adminis-
tered 7 days after IGIV therapy initiation. During her stay
in the hospital, she developed an episode of self-limited
hemolytic anemia with a low hemoglobin count (9.7 g/
dL; normal range > 12.0 g/dL) and increased total bilirubin
(5.72 mg/dL) and direct bilirubin (0.66 mg/dL) levels.
Progressive neurological improvement was observed and
the patient was discharged 21 days after admittance, main-
taining anisocoria and paresis of right eye adduction.
Complete resolution of clinical symptoms was observed
3 months after admission at follow-up visit. Repeated lab-
oratory workup in serum 5 months after the initial presen-
tation evidenced the persistence of PB19 DNA and
anti-PB19 IgM (1.10; positive ≥ 1.0) and IgG (32.50;
positive ≥ 1.0) antibodies but was negative regarding
antiganglioside antibody studies.
Discussion
A variety of neurological complications have been associated
with PB19 infection, including encephalitis, meningitis, myeli-
tis, stroke, cerebellar ataxia, and neuropathy (Barah et al. 2003;
Barah et al. 2014; Douvoyiannis et al. 2009), thus demonstrating
the ability of virus to involve either the central or peripheral
nervous system. The present report illustrates a case of PB19
infection characterized by cranial polyneuropathy and hemolytic
Fig. 1 Normal brain magnetic resonance imaging (axial T2 FLAIR)
Table 1 Causes of multiple cranial neuropathies involving the second and third cranial nerves
Infectious Inflammatory Vascular Neoplastic Other
Viruses: Sarcoidosis Carotid cavernous fistula Head and neck tumors Iatrogenic
Epstein-Barr virus Systemic lupus erythematosus Carotid cavernous aneurysm Neural tumors Traumatic
Human immunodeficiency virus Churg-Strauss syndrome Cavernous sinus thrombosis Hematologic malignancies
Varicella zoster virus Wegener granulomatosis Sickle cell anemia Metastatic lesions











anemia in an immunologically healthy woman. Interestingly, no
other typical PB19-related symptoms such as rash or arthropathy
were observed. Visual loss and ophthalmoplegia are often
caused by infectious, inflammatory, neoplastic, and vascular
processes (Table 1) (Keane 2005). Detailed microbiological
and virological tests ruled out a variety of acute infections, but
showed elevated titers of PB19 IgM and IgG. Other inflamma-
tory, neoplastic, or vascular disorders were also excluded based
on normal imaging and autoimmune studies. The diagnosis of
acute PB19 infection was established with detection of positive
DNA and anti-PB19 IgM antibodies in blood samples. As PB19
DNA may be detectable for extended periods of time in serum
(Musiani et al. 1995), its detection does not indicate acute infec-
tion. However, in our case, the presence of immunoglobulin M
during the acute neurological deficit, together with the simulta-
neous development of self-limited hemolytic anemia, suggests a
pathogenic role of PB19. Although not completely understood,
the pathogenesis of PB19 is complex and several mechanisms
may be involved during a single infection, including direct ef-
fects of the viral particle, dysregulated immune response with
cytokine up-regulation, immune complex deposition, and cyto-
toxic properties of NS1 protein (Barah et al. 2003). In addition,
PB19 infection has been shown to be a trigger for development
of a vast array of autoimmune conditions and autoantibody pro-
duction (Kerr 2016). In our case, the transient detection of
antiganglioside GD1b antibodiesmight represent the pathogenic
mechanism by which PB19 affected the central and peripheral
nervous system. Antiganglioside antibodies were previously de-
scribed in PB19-associated Guillain-Barré syndrome (Yamaoka
et al. 2000) but not in PB19-related central nervous system
manifestations. In our view, PB19 infection induced serum an-
tibody production against GD1b by means of an eventual mo-
lecular mimicry mechanism (Kerr 2016). The concept of PB19-
induced immune dysfunction led to treatment of its neurological
complications with corticosteroids and IGIV, though numerous
patients improve spontaneously (Qiu et al. 2017). Our patient
was primarily treated with IVIG and later with methylpredniso-
lone due to incomplete recovery. Fortunately, subsequent reso-
lution of symptoms was observed 3 months after disease onset
despite the persistence of PB19 DNA and anti-PB19 IgM anti-
bodies 5 months after the initial presentation. In conclusion, our
report provides evidence that PB19 could affect both the central
and peripheral nervous system, possibly by triggering an auto-
immune mechanism that leads to autoantibody production.
Furthermore, our case also suggests that investigation of PB19
infection should be considered even in the absence of typical
associated features and regardless of immune status.
References
Barah F, Vallely PJ, Cleator GM, Kerr JR (2003) Neurological manifesta-
tions of human parvovirus B19 infection. RevMedVirol 13:185–199
Barah F, Whiteside S, Batista S, Morris J (2014) Neurological aspects of
human parvovirus B19 infection: a systematic review. Rev Med
Virol 24:154–168
Broliden K, Tolfvenstam T, Norbeck O (2006) Clinical aspects of parvo-
virus B19 infection. J Intern Med 260:285–304
Douvoyiannis M, Litman N, Goldman DL (2009) Neurologic manifesta-
tions associated with parvovirus B19 infection. Clin Infect Dis 48:
1713–1723
Keane JR (2005) Multiple cranial nerve palsies: analysis of 979 cases.
Arch Neurol 62:1714–1717
Kerr JR (2016) The role of parvovirus B19 in the pathogenesis of auto-
immunity and autoimmune disease. J Clin Pathol 69:279–291
Musiani M, Zerbini M, Gentilomi G, Plazzi M, Gallinella G, Venturoli S
(1995) Parvovirus B19 clearance from peripheral blood after acute
infection. J Infect Dis 172:1360–1363
Qiu J, Söderlund-Venermo M, Young NS (2017) Human Parvoviruses.
Clin Microbiol Rev 30:43–113
Yamaoka Y, Isozaki E, Kagamihara Y, Matsubara S, Hirai S, Takagi K
(2000) A case of Guillain-Barré syndrome (GBS) following human
parvovirus B19 infection. Rinsho Shinkeigaku 40:471–475
J. Neurovirol.
